Compounds > 2,2,2-trifluoroethyl methacrylate
Page last updated: 2024-12-05

2,2,2-trifluoroethyl methacrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2,2,2-Trifluoroethyl methacrylate (TFEMA) is a fluorinated monomer that has gained significant interest in materials science due to its unique properties. TFEMA can be synthesized through various methods, including the reaction of methacryloyl chloride with 2,2,2-trifluoroethanol in the presence of a base. It exhibits a low glass transition temperature (Tg), high refractive index, and excellent chemical resistance, making it a valuable component in various applications. TFEMA is often incorporated into polymers to enhance their properties, such as optical transparency, weather resistance, and biocompatibility. Its ability to form highly fluorinated polymers with unique surface properties has led to its use in coatings, adhesives, and biomedical devices. The presence of the trifluoromethyl group in TFEMA imparts hydrophobic and oleophobic characteristics, making it suitable for applications involving water repellency and stain resistance. Researchers are exploring the use of TFEMA in advanced materials, including optical fibers, microelectronics, and drug delivery systems, due to its potential to enhance performance and functionality.'

Cross-References

ID SourceID
PubMed CID9608
SCHEMBL ID36595
MeSH IDM0132702

Synonyms (37)

Synonym
2,2,2-trifluoroethyl methacrylate
nsc-32617
trifluoroethyl methacrylate
methacrylic acid,2,2-trifluoroethyl ester
nsc32617
352-87-4
2,2-trifluoroethyl methacrylate
2,2,2-trifluoroethyl methacrylate, contains 50-200 ppm mehq as inhibitor, 99%
2,2,2-trifluoroethyl 2-methylprop-2-enoate
54802-79-8
AKOS005063599
methacrylic acid 2,2,2-trifluoroethyl ester
M0738
2,2,2-trifluoroethyl methacrylate, stab. w/ 100 ppm mehq
2-methyl-2-propenoic acid 2,2,2-trifluoroethyl ester
A822708
2,2,2-tris(fluoranyl)ethyl 2-methylprop-2-enoate
methacrylic acid, 2,2,2-trifluoroethyl ester
nsc 32617
2-propenoic acid, 2-methyl-, 2,2,2-trifluoroethyl ester
einecs 206-525-3
FT-0609037
FD2010
SCHEMBL36595
DTXSID7059856
W-106680
2,2,2-trifluoroethyl 2-methylacrylate #
mfcd00274739
2-propenoic acid, 2-methyl-, trifluoroethyl ester
mfcd00013576
2,2,2-trifluoroethyl-methacrylate
2,2,2-trifluoroethyl methacrylate (stabilized with mehq)
2,2,2-trifluoroethyl methacrylate, (stabilized with mehq)
2,2,2-trifluoroethyl methacrylate, contains 100 ppm mehq as stabilizer, 98%
AS-48910
EN300-7692027
CS-W017819
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's6 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.67 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		2.0510ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
benzene
[no description available]		2.0510aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
chloroform
Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.		2.0510chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
dimethylformamide
Dimethylformamide: A formamide in which the amino hydrogens are replaced by methyl groups.. N,N-dimethylformamide : A member of the class of formamides that is formamide in which the amino hydrogens are replaced by methyl groups.		2.0510formamides;
volatile organic compound		geroprotector;
hepatotoxic agent;
polar aprotic solvent
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.0510aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
methylmethacrylate
Methylmethacrylate: The methyl ester of methacrylic acid. It polymerizes easily to form POLYMETHYL METHACRYLATE. It is used as a bone cement.. methyl methacrylate : An enoate ester having methacrylic acid as the carboxylic acid component and methanol as the alcohol component.		2.0810enoate ester;
methyl ester		allergen;
polymerisation monomer
benzoyl peroxide
Benzoyl Peroxide: A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry.		2.0510carbonyl compound
ethylene dimethacrylate
ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.		2.0510enoate esterallergen;
cross-linking reagent;
polymerisation monomer
tetrahydrofuran
oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.		2.0510cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
n-butyl acrylate
butyl acrylate : An acrylate ester obtained by the formal condensation of the hydroxy group of butan-1-ol with the carboxy group of acrylic acid.		2.0810acrylate ester
ethyl acetate
ethyl acetate : The acetate ester formed between acetic acid and ethanol.		2.0510acetate ester;
ethyl ester;
volatile organic compound		EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite
hydroxyethyl methacrylate
hydroxyethyl methacrylate: many of cited refs are for gel which refers to polymeric form of above cpd: POLYHYDROXYETHYL METHACRYLATE. 2-hydroxyethyl methacrylate : An enoate ester that is the monomethacryloyl derivative of ethylene glycol.		2.4120enoate esterallergen;
polymerisation monomer
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.0510diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
fluorides
[no description available]		2.0510halide anion;
monoatomic fluorine
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0510benzenes;
phenyl acetates
trimethoxyvinylsilane
[no description available]		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.1710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1710